Description
ChemicalBook > CAS DataBase List > Dabrafenib Mesylate

Dabrafenib Mesylate

Description
Product Name
Dabrafenib Mesylate
CAS No.
1195768-06-9
Chemical Name
Dabrafenib Mesylate
Synonyms
Dabrafenib Mesylate;GSK 2118436B;Dapafini mesylate;abrafenibmesylate;Dabrfenib Mesylate;GSK2118436 Mesylate;GSK 2118436 Mesylate;GSK-2118436 Mesylate;Dabrafenib Mesylate (API);Debrafenib Mesylate (API)
CBNumber
CB72630077
Molecular Formula
C24H24F3N5O5S3
Formula Weight
615.66
MOL File
1195768-06-9.mol
More
Less

Dabrafenib Mesylate Property

Melting point:
>234oC (dec.)
storage temp. 
Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility 
DMSO (Slightly, Heated), Methanol (Slightly)
form 
White solid.
color 
White to Off-White
Stability:
Hygroscopic
InChIKey
YKGMKSIHIVVYKY-UHFFFAOYSA-N
SMILES
S(O)(=O)(=O)C.FC1C(=CC=CC=1C1N=C(C(C)(C)C)SC=1C1C=CN=C(N)N=1)NS(C1C(=CC=CC=1F)F)(=O)=O
More
Less

Safety

HS Code 
2935909099
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
35251
Product name
Dabrafenib (mesylate)
Purity
≥98%
Packaging
50mg
Price
$70
Updated
2026/04/30
Cayman Chemical
Product number
35251
Product name
Dabrafenib (mesylate)
Purity
≥98%
Packaging
100mg
Price
$132
Updated
2026/04/30
Cayman Chemical
Product number
35251
Product name
Dabrafenib (mesylate)
Purity
≥98%
Packaging
500mg
Price
$347
Updated
2026/04/30
Cayman Chemical
Product number
35251
Product name
Dabrafenib (mesylate)
Purity
≥98%
Packaging
1g
Price
$624
Updated
2026/04/30
Tocris
Product number
7223
Product name
Dabrafenibmesylate
Purity
≥98%(HPLC)
Packaging
50
Price
$149
Updated
2021/12/16
More
Less

Dabrafenib Mesylate Chemical Properties,Usage,Production

Description

Dabrafenib Mesylate(1195768-06-9) is a salt form of Dabrafenib. Dabrafenib is an inhibitor of certain mutated forms of BRAF kinase, several of which may be associated with stimulating tumour growth (e.g. the BRAF V600E mutation), and Dabrafenib is also an inhibitor of BRAF V600-mutation positive cancer cell growth, both in vitro and in vivo.

Description

Dabrafenib mesylate, sold by GlaxoSmithKline under the trade name Tafinlar, was approved by the U.S. FDA in May 2013 for the treatment of metastatic BRAF-mutant melanoma. Dabrafenib reversibly inhibits the BRAF(V600E) mutant kinase as a selective ATP-competitive inhibitor which results in tumor regression.

Uses

Dabrafenib is an inhibitor of mutated BRAF kinase and has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.

Definition

ChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of dabrafenib and methanesulfonic acid. Used for treatment of metastatic melanoma.

Synthesis

Commercially available fluoroaniline 40 was first converted to sulfonamide 42 in 91% yield by treatment with 2,5-difluorobenzenesulfonyl chloride (41) in the presence of pyridine. Next, deprotonation of 2-chloro-4-methylpyrimidine (43) with lithium bis(trimethylsilyl)amide (LHMDS) followed by addition to ester 42 afforded chloropyrimidine 44 in 72% yield. Bromination followed by thiazole formation through the use of 2,2-dimethylpropanethioamide gave the penultimate target 45 in 80% over two steps. Chloropyrimidine 45 was subjected to SNAr conditions with ammonium hydroxide to furnish the aminopyrimidine in 88% yield, and this was followed by exposure to methanesulfonic acid to afford dabrafenib mesylate (VI) in 85% yield.

target

Raf

storage

Store at -20°C

References

[1]namba h, nakashima m, hayashi t, hayashida n, maeda s, rogounovitch ti, ohtsuru a, saenko va, kanematsu t, yamashita s. clinical implication of hot spot braf mutation, v599e, in papillary thyroid cancers. j. clin. endocrinol. metab. 2003; 88 (9): 4393–7.
[2]tan yh, liu y, eu kw, ang pw, li wq, salto-tellez m, iacopetta b, soong r. detection of braf v600e mutation by pyrosequencing. pathology 2008; 40 (3): 295–8.
[3]davies h, bignell gr, cox c, et al. mutations of the braf gene in human cancer. nature. 2002; 417: 949-954.
[4]ma xh, piao sf, dey s, mcafee q, karakousis g, villanueva j, hart ls, levi s, hu j, zhang g, lazova r, klump v, pawelek jm, xu x, xu w, schuchter lm, davies ma, herlyn m, winkler j, koumenis c, amaravadi rk. targeting er stress-induced autophagy overcomes braf inhibitor resistance in melanoma. j clin invest. 2014; 124(3): 1406-17.

Dabrafenib Mesylate Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Dabrafenib Mesylate Suppliers

JINAN RUIFENG PHARMACEUTICAL TECHNOLOGY CO.,LTD
Tel
18668921571 18668921571;
Email
liujnlz@126.com
Country
China
ProdList
22
Advantage
58
Shenzhen HwaGen Pharmaceutical Co.,Ltd
Tel
Q:3003761227 17722620669
Email
liangcong.yi@rafflespt.com
Country
China
ProdList
263
Advantage
58
Beijing Mesochem Technology Co., Ltd.
Tel
010-57862036 18811083386
Email
msales@mesochem.com
Country
China
ProdList
210
Advantage
58
Enki Biopharmaceuticals(Shanghai) Limited
Tel
+86-21 5768 0965 +86-13916707528
Fax
(21) 5768 0922
Email
yusu@enkibiopharma.com
Country
China
ProdList
47
Advantage
55
Shandong Chenxi Pharmaceutical Co., Ltd.
Tel
+86-0531-88803416 13153166250
Fax
0531-88803416
Email
sales@chemedpharma.com
Country
China
ProdList
171
Advantage
58
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
Chembest Research Laboratories Limited
Tel
021-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6003
Advantage
61
Adamas Reagent, Ltd.
Tel
400-6009262 15618770481
Fax
021-64823266
Email
yhx@titansci.com
Country
China
ProdList
14100
Advantage
59
Jinan Trio PharmaTech Co., Ltd.
Tel
0531-88811783
Fax
+86 (531) 55696010 QQ 1762738062
Email
sales@trio-pharmatech.com
Country
China
ProdList
1856
Advantage
62
NCE Biomedical Co.,Ltd.
Tel
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax
+86-27-87599188
Country
China
ProdList
1493
Advantage
55
More
Less

View Lastest Price from Dabrafenib Mesylate manufacturers

Zison Pharmaceutical (Shandong) Co., Ltd.
Product
Dabrafenib mesylate 1195768-06-9
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
>99.5% by HPLC
Supply Ability
100kg/month
Release date
2023-02-18
Zison Pharmaceutical (Shandong) Co., Ltd.
Product
Dabrafenib Mesylate 1195768-06-9
Price
US $0.00/g
Min. Order
10g
Purity
99.9
Supply Ability
20kgs
Release date
2024-05-24
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
Product
Dabrafenib Mesylate 1195768-06-9
Price
US $1.00/g
Min. Order
5g
Purity
More Than 99%
Supply Ability
100kg/Month
Release date
2024-08-09

1195768-06-9, Dabrafenib MesylateRelated Search:


  • Dabrafenib Mesylate (GSK-2118436)
  • Dabrafenib Mesylate(GSK-2118436B)
  • Dabrafenib Mesylate
  • GSK 2118436 Mesylate
  • GSK 2118436B
  • GSK2118436 Mesylate
  • GSK-2118436 Mesylate
  • Dabrafenib Mesylate (API)
  • GSK 2118436 methanesulfonate salt
  • N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide methanesulfonate
  • Dapafini mesylate
  • DABRAFENIB MESYLATE (GSK 2118436B);GSK-2118436 MESYLATE;GSK2118436 MESYLATE;GSK 2118436 MESYLATE
  • N-(3-(5-(2-Aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate
  • GSK2118436 Ms salt, Dabrafenib Ms salt, GSK2118436A Ms salt
  • Debrafenib Mesylate (API)
  • Dabrafenib, Methanesulfonate Salt
  • Dabrfenib Mesylate
  • N-(3-(5-(2-Aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzen
  • Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, methanesulfonate (1:1)
  • abrafenibmesylate
  • Dabrafenib Mesylate (GSK2118436 Mesylate
  • N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonic acid
  • Dalafenib methanesulfonate
  • Dabrafenib Mesylate, 10 mM in DMSO
  • 1195768-06-9
  • C23H20F3N5O2S2CH4O3S
  • C24H24F3N5O5S3
  • Raf B protein kinase inhibitor
  • API